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Abstract
Background: uPAR and MMP-9, which play critical roles in tumor cell invasion, migration and angiogenesis, have
been shown to be associated with lipid rafts.
Methods: To investigate whether cholesterol could regulate uPAR and MMP-9 in breast carcinoma, we used MbCD
(methyl beta cyclodextrin, which extracts cholesterol from lipid rafts) to disrupt lipid rafts and studied its effect on
breast cancer cell migration, invasion, angiogenesis and signaling.
Results: Morphological evidence showed the association of uPAR with lipid rafts in breast carcinoma cells. MbCD
treatment significantly reduced the colocalization of uPAR and MMP-9 with lipid raft markers and also significantly
reduced uPAR and MMP-9 at both the protein and mRNA levels. Spheroid migration and invasion assays showed
inhibition of breast carcinoma cell migration and invasion after MbCD treatment. In vitro angiogenesis studies
showed a significant decrease in the angiogenic potential of cells pretreated with MbCD. MbCD treatment
significantly reduced the levels of MMP-9 and uPAR in raft fractions of MDA-MB-231 and ZR 751 cells.
Phosphorylated forms of Src, FAK, Cav, Akt and ERK were significantly inhibited upon MbCD treatment. Increased
levels of soluble uPAR were observed upon MbCD treatment. Cholesterol supplementation restored uPAR
expression to basal levels in breast carcinoma cell lines. Increased colocalization of uPAR with the lysosomal marker
LAMP1 was observed in MbCD-treated cells when compared with untreated cells.
Conclusion: Taken together, our results suggest that cholesterol levels in lipid rafts are critical for the migration,
invasion, and angiogenesis of breast carcinoma cells and could be a critical regulatory factor in these cancer cell
processes mediated by uPAR and MMP-9.
Background
Lipid rafts are detergent-insoluble, cholesterol-rich
microdomains and have been attributed to several cellu-
lar functions. Lipid rafts play critical roles in the regula-
tion of several membrane receptors, apoptosis, cell
adhesion, and protein sorting during endocytosis and
exocytosis [1,2]. Lipid rafts have also been implicated in
invasion, viral entry and egress, cholesterol metabolism,
endocytosis, etc. but many of their functions are still
unknown [3]. Lipid rafts are known to be abundant in
signaling molecules and to regulate signal transduction
by activating or suppressing phosphorylation cascades
related to growth, survival and many other physiological
processes [4]. They are also known to function as mole-
cular platforms that organize appropriate molecules for
specific signaling pathways [5].
uPAR, a glycosylphosphatidylinositol-anchored mem-
brane protein with multiple functions in extracellular
proteolysis, cell adhesion, cell migration and cell prolif-
eration, is found in both the lipid rafts and in more
fluid regions of the plasma membrane [6]. Cunningham
and colleagues [7] have shown that dimerized uPAR
partitions preferentially to detergent-resistant lipid rafts.
uPAR seems to associate with L-selectin in human
neutrophil lipid rafts but not with the complement
receptor CR3 [8]. Matrix metalloproteinases comprise a
family of zinc-binding endopeptidases that are capable
of degrading ECM components, including collagen and
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roles in cancer, infectious disease, wound healing,
inflammation and many vascular diseases [10-13]. Zhang
et al. [14] have shown that MMP-9 associates with lipid
rafts in highly metastatic sublines from Lewis Lung
carcinoma.
Cholesterol is a important component of lipid rafts
and is known to play a important role in maintaining
membrane integrity, trafficking, signal transduction and
fluidity [15-17]. Cholesterol depletion results in the dis-
organization of lipid raft microdomains and also the dis-
sociation of proteins [18] that are bound to the lipid
raft. Cholesterol depleting agents, such as filipin, nysta-
tin or methyl beta cyclodextrin (MbCD), remove choles-
terol and cause disruption of lipid rafts within a short
period of time. MbCD is a strictly surface acting agent,
can selectively and rapidly remove cholesterol from the
plasma membrane in preference to other membrane
lipids, and has been widely used in studying the effects
of cholesterol depletion on lipid raft assembly. More-
over, cholesterol accumulation is known to be associated
in many tumors, including prostate cancer and oral can-
cer [19,20], and dysregulated in lung and breast cancers
[21,22].
As uPAR and MMP-9 are known to be associated
with cholesterol-enriched lipid rafts, the present study
investigated the effects of cholesterol depletion-mediated
lipid raft disruption by MbCD treatment on uPAR and
MMP-9 in breast carcinoma cells. Overall, in our study,
we demonstrated that MbCD treatment inhibited raft-
associated uPAR and MMP-9 activity in MDA-MB-231
and ZR 751 cells. MbCD treatment down regulated the
p h o s p h o r y l a t i o no fS r c ,F A K ,C a v ,E R K ,a n dA k ta n d
targeted uPAR to the lysosomal pathway in breast carci-
noma cells. Our results show the implications of choles-
terol depletion in uPAR and MMP-9-related cancer cell
functions and provide a biological basis for targeting
lipid rafts in future breast cancer therapy and treatment.
Methods
Cells, antibodies and reagents
M D AM B 2 3 1 ,Z R7 5 1 ,H M E Cc e l l sw e r ec u l t u r e d
according to methods established in our laboratory (24).
MbCD, nystatin and NAC were purchased from Sigma
(St. Louis, MO). Anti-Src-pY416, anti-Src-pY527, and
pAkt were purchased from Cell Signaling (Danvers, MA).
Antibodies for the phosphorylated and total forms of
ERK, FAK, PI3K, Akt and Cav were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies
against MMP-9, flotillin and CD71 were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). The uPAR
antibody was purchased from R&D Systems (Minneapo-
lis, MN). Secondary antibodies were also purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Alexa Fluor
antibodies and Vybrant lipid raft labeling kit were pur-
chased from Invitrogen (Carlsbad, CA). Caveolae/raft iso-
lation kit was purchased from Sigma (St. Louis, MO).
Cytotoxicity assays
Target cells were incubated with Dulbecco’s modified
Eagle medium (DMEM) containing different concentra-
tions of MbCD for 1, 4, 24 and 48 hrs. Supernatants
were collected and assessed for cellular toxicity using a
LDH cytotoxicity assay kit (Promega, Madison, WI) in
accordance with the manufacturer’s instructions.
Determination of cellular cholesterol by Amplex Red
cholesterol assay
MDA-MB-231 and ZR 751 cells were washed twice with
phosphate-buffered saline (PBS) and then incubated at
37°C for 1 hr with different concentrations of MbCD in
DMEM. After two washes with PBS, cells were har-
vested for cholesterol measurement assays as per the
manufacturer’s instructions (Molecular Probes Inc,
Eugene, OR).
Colocalization studies
Confluent MDA-MB-231 and ZR 751 cells grown in
eight-well chamber slides were left untreated or pre-
treated with different concentrations of MbCD for one
hour at 37°C, washed and labeled for lipid raft marker
flotiilin or with GM1 (lipid raft labeling kit, Molecular
Probes) as per the manufacturer’s instructions. The cells
were washed, fixed with 2% paraformaldehyde, permea-
bilized in 0.5% Triton X-100, and stained with primary
antibodies against uPAR, MMP-9, pFAK, pCav, pPI3K,
and GM1 overnight at 4°C. The cells were then washed,
incubated with appropriate secondary antibodies for 1
hr at room temperature, washed, mounted with anti-
fading agent containing DAPI, and examined under a
confocal fluorescence microscope. For colocalization
studies of uPAR and LAMP-1, MDA-MB-231 cells
grown in eight-well chamber slides were left untreated
or treated with 7.5 mM MbCD, fixed with 2% parafor-
maldehyde at indicated time points (1, 8 and 24 hrs),
and incubated with primary antibodies against uPAR
and LAMP-1. The cells were then washed and further
incubated with appropriate secondary Alexa Fluor
antibodies, and examined under a Olympus fluoview
confocal microscope.
Spheroid migration assay
MDA-MB-231 and ZR 751 cells (1.5 × 10
4)w e r es u s -
pended in the appropriate medium, seeded onto 0.5%
agar-coated plates, and cultured until spheroids formed.
Intact tumor spheroids were selected and transferred to
six-well plates. The spheroids were either left untreated
or treated with different concentrations of MbCD and
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with migrated cells were fixed with 10% buffered forma-
lin in PBS and stained using crystal violet staining solu-
tion. The spheroids were observed under a normal light
microscope and photographed at 20× and 40× magnifi-
cation using the DP controller imaging software.
Fibrin and gelatin zymography
Conditioned medium was collected from MDA-MB-231
and ZR 751 control cells and cells that were treated
with different concentrations of MbCD. MDA MB231
and ZR 751 cells pretreated with ruPA (10 ng/μl) and
rMMP-9 (2.5 ng/μl) were used as positive controls. The
conditioned media was subjected to fibrin and gelatin
zymography as described by Gondi et al. [23]. MMP-9
activity was quantified as arbitrary units and compared
with controls.
Preparation of RNA
Isolation of total RNA from treated and untreated cells
was carried out using the TRIzol reagent (Invitrogen,
Carlsbad, CA) according to the manufacturer’s
instructions.
Reverse transcription-PCR
Total RNA was isolated from cells in all treatment con-
ditions using the TRIzol reagent as per the standard
protocol. Total RNA was treated with DNAse I (Invitro-
gen, Carlsbad, CA) to remove contaminating genomic
DNA. PCR analysis was done using the one-step reverse
transcription-PCR kit (Invitrogen, Carlsbad, CA). Gly-
ceraldehyde 3-phosphate dehydrogenase (GAPDH) was
used as an internal control. The following primers were
used:
uPAR:5 ’-GAAGGAGAGAAGACGTGCAG-3’ sense
5’-GATCCAGCCAGGGCAGAG-3’ antisense
MMP-9:5 ’-TGGACGATGCCTGCAACGTG-3’
sense
5’-TGCCTTTGGACACGCACGAC-3’ antisense
GAPDH:5’-CGGAGTCAACGGATTTGGTCGTAT-
3’sense 5’-AGCCTTCTCCATGGTGGTGAAGAC
3’antisense
The PCR conditions were as follows: 95°C for 5 min,
followed by 30 cycles of 95°C for 1 min, and annealing
temperature set according to the AT and GC content of
the primers.
Western blotting
MDA-MB-231 and ZR 751 cells were either left
untreated or pretreated with different concentrations of
MbCD for 1 hr at 37°C. Total cell lysates were prepared
and resolved on SDS-polyacrylamide gels, transferred
onto nitrocellulose paper, and immunoblotted with
appropriate primary antibodies.
uPAR immunoassay
Untreated MDA-MB-231 and ZR 751 cells and cells
pretreated with different concentrations of MbCD for 1
hr at 37°C were allowed to incubate with serum-free
medium for 24 and 48 hrs. Conditioned medium col-
lected from the treated and untreated cells were sub-
jected to uPAR immunoassay as per the manufacturer’s
instructions (R&D Systems, Minnepolis, MN).
In vitro angiogenesis assay
MDA-MB-231 cells (2 × 10
4) and ZR 751 cells were
seeded in 100-mm plates and either left untreated or
treated with different concentrations of MbCD for 1 hr
at 37°C. After treatment, the medium was removed;
washed and serum-free medium was added. Conditioned
medium was collected after 24 hrs. Human microvascu-
lar endothelial cells (HMEC) were cultured in the condi-
tioned medium for 24 hrs. After the incubation period,
the medium was removed, and the cells were stained
with Hema-3 stain (Fisher Diagnostics, Fisher Scientific
Company, Middletown, VA) and examined under a
microscope. Image Pro software (Media Cybernetics, Sil-
ver Spring, MD) was used for quantification of angio-
genesis. The degree of angiogenesis was measured by
the following method: number of branch points and the
total number of branches per point, with the product
indicating the degree of angiogenesis.
Matrigel invasion assay
MDA-MB 231 cells (1 × 10
6) were left untreated or pre-
treated with different concentrations of MßCD for 1 h
at 37°C, washed and allowed to invade through matrigel
-c o a t e dt r a n s w e l li n s e r t s( 8μM pores) for 24 hrs. Cells
which invaded through the Matrigel coated inserts were
stained, counted and photographed under an Olympus
light microscope at 20× magnification. Quantitative esti-
mation of invasion was done as per the method pre-
viously established in our laboratory [24].
Biochemical isolation of detergent-resistant domain
association and cholesterol depletion
MDA-MB-231 and ZR 751 cells (1-2 × 10
7/25-cm
2 cul-
ture flasks) were serum starved for 14 to 16 hrs, and
cells were left untreated, pretreated with 7.5 mM MbCD
or 10 mM MbCD for 1 hr at 37°C to allow for choles-
terol depletion (60%). Lipid raft fractions were isolated
using the Raft Isolation Kit (Sigma, Inc., St.Louis, MO)
Rafts were also isolated using the procedure of Raghu
et al. [3]. The whole procedure was performed at 0-4°C.
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to electrophoresis and Western blotting. Fractions 3, 4,
and 5 were pooled and marked as raft fractions and
fractions 6, 7, and 8 were labeled as non-raft fractions.
Raft fractions and non-raft fractions were characterized
based on the specificity to caveolin and transferrin in
MDA-MB-231 cells and flotillin and transferrin in ZR
751 cells.
Cholesterol depletion and supplementation experiments
Cholesterol depletion was done by treating cells with
different concentrations of MbCD for 1 hr at 37°C fol-
lowed by washing and incubation with serum-free
DMEM for the indicated time periods. For cholesterol
supplementation, the cells were treated initially with 10
mM MbCD, and then the cells were incubated for dif-
ferent time periods with or without the cholesterol
MbCD complexes. At the end of each indicated time
period, the cells were washed and incubated with
serum-free medium, and the lysates were collected for
western blot analysis.
Statistical analysis
All statistical analyses were carried out using Excel soft-
ware. The significance of the differences was determined
using an independent samples t-test. A p value of less
than 0.05 was regarded as statistically significant.
RESULTS: uPAR colocalizes with GM1 and flotillin, two
lipid raft markers, in MDA-MB-231 and ZR 751 cells
As previously reported [6,7], uPAR, a GPI-anchored
receptor protein, is a lipid raft-associated protein. In
Figure 1A, GM1 staining, which is an LR specific mar-
ker, was observed predominantly in the cell periphery of
unstimulated MDA-MB-231 cells (Figure 1A, panel a).
Also, uPAR staining was seen more near the plasma
membrane (Figure 1A, panel b). A very clear margin of
colocalization of uPAR the with LR marker GM1 was
observed near the plasma membrane of MDA-MB-231
cells (Figure 1A, panel c). Colocalization studies were
done with GM1 at 1 h and 24 h time points after 1 h
treatment with MbCD. In cells pretreated with 7.5 mM
MbCD, we found disrupted GM1 spots in the cells
(Figure 1A, panel d). In addition, we observed inhibition
o fu P A Rs t a i n i n ga tt h ep l a s m am e m b r a n e( F i g u r e1 A ,
panel e). Moreover, we did not observe colocalization of
GM1 with uPAR in MbCD-treated cells (Figure 1A,
panel f). Morphological analysis revealed the association
of uPAR with another lipid raft marker, flotillin, in ZR
751 cells (Figure 1B, panels a to c). In cells pretreated
with MbCD, we observed significant inhibition of the
colocalization of flotillin with uPAR in ZR 751 cells
(Figure 1B, panels d to f).
Inhibition of uPA and uPAR protein expression by the
lipid raft disrupting agent MbCD in MDA-MB-231 and ZR
751 cells
In untreated cells, we observed increased activity of uPA
in MDA-MB-231 and ZR 751 cells as assessed by fibrin
zymography (Figure 1C, lane 2 top panel (MDA
MB231), bottom panel, lane 2(ZR 751). In cells treated
with MbCD, inhibition of uPA activity was observed at
24 h time point (Figure 1C top panel lane 3 & 4 (MDA
MB 231) and bottom panel lane 3 & 4 (ZR 751). Condi-
tioned medium from cells treated with ruPA (10 ng/μl)
w a st a k e na sap o s i t i v ec o n t r o l( F i g u r e1 Cl a n e1 ,t o p
and bottom panel). Lysates from two time points namely
at 1 hr and 24 hrs showed significant decreases in uPAR
protein levels in LR-disrupted cells when compared with
untreated controls. The decrease in expression levels
was also dose-dependent; 10 mM MbCD treatment
resulted in 40% decrease in expression levels while 7.5
mM MbCD treatment resulted in 30% decrease in
expression levels in MDA-MB-231 cells (Figure 1D,
lanes 2 and 3). Equal loading of total lysates was con-
firmed with GAPDH. In ER-positive breast cancer cells,
we observed a similar pattern of uPAR expression in
unstimulated cells. In cells treated with different con-
centrations of MbCD, we observed a 30-35% reduction
in uPAR protein levels (Figure 1E, lanes 2 and 3). uPAR
expression in ZR 751 cells was observed for up to 24
hrs (Figure 1E, lanes 2 and 3). These results suggest that
lipid raft disruption by plasma membrane cholesterol
depletion plays an active role in uPA and uPAR expres-
sion levels in both MDA-MB-231 and ZR 751 cells.
MMP-9 colocalizes with the lipid raft marker GM1 in
MDA-MB-231 and with flotillin in ZR 751 cells
Previous studies have shown that MMP-9 is associated
with lipid rafts (14). To ascertain if such an association
exists in breast carcinoma cells, we used untreated and
MbCD-treated breast carcinoma cells and checked for
colocalization of MMP-9 with GM1 in MDA-MB-231
cells and with flotillin in ZR 751 cells. As expected, we
observed lipid raft staining at the cell periphery in MDA-
MB-231 cells (Figure 2A, panel a), and MMP-9 staining
was more concentrated at the leading edge of the cells
(Figure 2A, panel b). In the merged image, we observed
colocalization of MMP-9 with the lipid raft marker GM1
at the leading edge and at the margin of the cell, suggest-
ing that MMP-9 associates with lipid rafts at the leading
edge and in the periphery of the cells. When the cells
were pretreated with 7.5 mM MbCD for 1 hr at 37°C, we
did not observe colocalization of MMP-9 and GM1 (Fig-
ure 2A, panels d to f). In ZR 751 cells, we observed colo-
calization of MMP-9 with the lipid raft marker flotillin in
untreated cells (Figure 2B, panels a to c) while in cells
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Page 4 of 17Figure 1 uPAR colocalizes with lipid rafts in MDA-MB-231 and ZR 751 cells. (A) and (B) MDA-MB-231 and ZR 751 cells grown in 8-well
chamber slides were serum starved for 12-16 hrs, either left untreated or pretreated with MbCD, washed, labeled for the lipid raft marker GM1,
fixed, permeabilized and blocked with 5% BSA for 1 hr. Then, cells were washed, labeled with anti-uPAR antibody for 1 hr at room temperature,
washed, and stained for 1 hr with Alexa Fluor 488 (uPAR) and Alexa Fluor 594 (GM1) conjugated secondary antibodies at room temperature.
Panels a to c: untreated cells; panels d to f: cells pretreated with 7.5 mM MbCD. The insets in panel’s c and f show an enlarged view of the
colocalization. Arrows indicate colocalization of uPAR with GM1 in MDA-MB-231 cells and uPAR and flotillin in ZR 751 cells before and after
treatment with MbCD. Scale bars: 10 μM. (C) Inhibition of uPA activity by fibrin zymography. MDA-MB-231 and ZR 751 cells were left untreated
or pretreated with different concentrations of MbCD, treated with ruPA (positive control) (10 ng/μl) washed and serum-free medium was added.
After 24 hrs, conditioned medium was collected, and uPA activity was measured by fibrin zymography in MDA-MB-231 and ZR 751 cells.
Densitometric analysis was done using the ImageJ software (**p < 0.001). (D) Western blot analysis of uPAR protein expression at 1 hr and 24 hr
time points in cell lysates from MDA-MB-231 (D) and ZR 751 (E) cells either left untreated or pretreated with different concentrations of MbCD.
Western blot analysis was performed with an antibody specific for uPAR. GAPDH was simultaneously immunodetected to verify equal loading of
cell lysates. Densitometric analysis was done for uPAR expression (*p < 0.01). The result provided is a representative experiment repeated 3 times
with concordant results.
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Page 5 of 17Figure 2 MMP-9 colocalizes with lipid rafts in MDA MB 231 and ZR 751 cells. (A) and (B) MDA-MB-231 and ZR 751 cells grown in 8-well
chamber slides were serum starved for 12-16 hrs, either left untreated or pretreated with different concentrations of MbCD, washed, labeled for
the lipid raft marker GM1 using vibrant lipid raft labeling kit, fixed, permeabilized and blocked with 5% BSA for 1 hr. Then, cells were washed,
labeled with anti-MMP-9 antibody for 1 hr at room temperature, washed and stained for 1 hr with Alexa Fluor 488 (MMP-9) conjugated
secondary antibody at room temperature. Panels a to c: untreated cells; panels d to f: cells pretreated with 7.5 mM MbCD. The insets in panel’sc
to f showed an enlarged view of the colocalization. Arrows indicate colocalization of MMP-9 with GM1 in MDA-MB-231 cells and with flotillin in
ZR 751 cells. Scale bars: 10 μM. (C) Inhibition of MMP-9 activity as shown by gelatin zymography in MDA-MB-231 and ZR 751 cells left untreated,
pretreated with different concentrations of MBCD or treated with rMMP-9 (2.5 ng/μl). Densitometric analysis was done using the ImageJ software
(**p < 0.001). (D) Western blot analysis of MMP-9 protein expression at 1 hr and 24 hr time points in cell lysates from MDA-MB-231 (D) and ZR
751 (E) cells left untreated or pretreated with different concentrations of MbCD. Western blot analysis was performed with an antibody specific
for MMP-9. GAPDH was simultaneously immunodetected to verify equal loading of the lysates. Densitometric analysis was done for MMP-9
expression (*p < 0.01, **p < 0.001). The result provided is a representative experiment repeated three times with concordant results.
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Page 6 of 17treated with 7.5 mM MbCD, we observed significant
inhibition of the colocalization of MMP-9 with flotillin
(Figure 2B, panels d to f). These results suggest that
MMP-9 colocalizes with lipid rafts, and lipid raft disrup-
tion by cholesterol depletion inhibits this association.
Lipid raft disruption decreases MMP-9 activity and
protein expression in MDA-MB-231 cells and ZR 751 cells
Morphological studies have shown that MMP-9, a zinc
endopeptidase, associates with lipid rafts at the periph-
ery and at the leading edge of the cells. To ascertain if
lipid raft disruption by cholesterol depletion inhibits
MMP-9 activity, we determined MMP-9 activity using
gelatin zymography. Consistent with our previous results
[24], we observed increased MMP-9 activity in condi-
tioned medium at the 24 hr time point in untreated
cells (Figure 2C, lane 1 top panel (MDA MB231) and
Figure 2C lane 2 bottom panel (ZR 751). However, in
the MbCD-treated cells, there was 25-35% decrease in
MMP-9 activity (Figure 2C, lanes 2 and 3 (MDA MB
231 and Figure 2C lane 3, 4 (ZR 751). As a positive
control the cells were treated with rMMP-9 (2.5 ng/μl)
(Figure 2C lane 4 top panel (MDA MB231) and Figure
2C lane 1 bottom panel (ZR 751). To further substanti-
ate our results, we wanted to determine if lipid raft dis-
ruption also affected the MMP-9 protein expression
levels in MDA-MB-231 and in ZR 751 cells. MMP-9
levels in the total cell lysates were measured using wes-
tern blotting. As shown previously, we observed a higher
level of MMP-9 expression in untreated cells (Figures
2D-E, lane 1) as compared with MDA-MB-231 and ZR
751 cells pretreated with different concentrations of
MbCD (Figure 2D, lanes 2 and 3). The MMP-9 expres-
sion levels in MDA-MB-231 cells showed a decrease in
MMP-9 protein levels up to 24 hrs in MbCD-treated
cells. Equal loading of lysates is demonstrated by
GAPDH expression (Figure 2D, top and bottom panel).
The MMP-9 expression levels in ZR 751 cells showed a
decrease in MMP-9 protein levels up to 1 hr in MbCD-
treated cells. At the 24 hr time point, we did not
observe significant changes in MMP-9 levels in untreated
and lipid raft-disrupted ZR 751 cells (Figure 2E, lanes 2
and 3). These results show that in both ER-positive and
ER-negative cell lines, lipid rafts are critical for uPAR and
MMP-9 expression and activity. The differences in
MMP-9 protein expression levels in MDA-MB-231 and
ZR 751 cells demonstrate the cell type variation in
MMP-9 levels mediated by lipid raft disruption.
Biochemical isolation of lipid rafts demonstrates uPAR
and MMP-9 in lipid raft fractions of MDA-MB-231 and ZR
751 cells
To determine whether treatment of MDA-MB-231 and
ZR 751 cells with various concentrations of MbCD and
nystatin efficiently extracted cholesterol and to check
whether the cholesterol levels remained depleted even
after 24 hrs, we assayed cellular cholesterol levels. As
shown in Figures 3A and 3B, after treatment with non-
toxic doses of the drugs, cellular cholesterol levels
decreased in a dose-dependent manner at both the 1 hr
and 24 hr time points in both of the cell lines tested.
With 50 and 100 μg concentrations of nystatin, we
observed a 20-30% reduction in ZR 751 cells at 1 hr and
24 hrs; in MDA-MB-231 cells, we observed a 25-40%
reduction in cellular cholesterol levels (Figures 3A-B).
With 5 mM, 7.5 mM and 10 mM MbCD, we found 20-
30% reduction in cellular cholesterol levels in ZR 751
cells and 25-55% reduction in MDA-MB-231 cells
(Figure 3A). In contrast, we did not observe a significant
change in cellular cholesterol levels when cells were
treated with 20 mM NAC (n-acetyl cysteine (a known
antioxidant) for 1 hr at 37°C (Figures 3A-B). To further
confirm that concentration of MbCD used is nontoxic
to the cells, we did the cellular cytotoxicity assay using
the Lactate dehydrogenase assay kit. Results showed that
both MDA MB231 and ZR 751 cells tolerated 5 mM,
7.5 mM and 10 mM concentrations of MbCD upto 48 h
time points and the concentrations used were nontoxic
to the cells. (Figure 3C). These results demonstrate that
both MbCD and nystatin were efficient in depleting or
chelating cholesterol from the lipid rafts of MDA-MB-
231 and ZR 751 cells under our testing conditions.
As shown previously in Figure 1C and Figure 2C,
when lipid rafts were disrupted by depletion of plasma
membrane cholesterol levels in MDA-MB-231 and ZR
751 cells, we observed decreased uPA and MMP-9 activ-
ity in the conditioned medium at the 24 hr time point.
In addition, we found significant decreases in uPAR and
MMP-9 protein levels in the LR-disrupted lysates as
compared with untreated lysates. Next, we determined
whether uPAR and MMP-9 are associated with LR
microdomains by biochemical isolation of lipid raft frac-
tions from both cell types. We carried out biochemical
isolation of lipid rafts using the detergent method [25].
Fractions 3, 4 and 5, which were positive for the lipid
raft marker caveolin (Figure 3A, left upper panel) and
negative for transferrin (Figure 4A, left bottom panel),
were pooled and labeled as lipid raft fractions. Fractions
6, 7 and 8, which were positive for transferrin, a non-
raft marker, (Figure 4A, right bottom panel) and nega-
tive for caveolin (Figure 4A, right upper panel), were
pooled and labeled as non-raft fractions. uPAR and
MMP-9 in the pooled raft fractions (3 to 5) and non-
raft fractions (6 to 8) were examined by immunoprecipi-
tation assays. Higher levels of uPAR and MMP-9 were
observed in raft fractions of both MDA-MB-231 and ZR
751 cells (Figures 4A-B) than in the non-raft fractions.
MbCD treatment significantly decreased the association
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little or no activity similar to non-raft fractions. These
results suggest that both uPAR and MMP-9 associate
with lipid rafts in MDA-MB-231 and ZR 751 cells.
Lipid raft disruption by MbCD inhibits uPAR and MMP-9
mRNA gene expression
As previously shown in Figure 1C-E and in Figure 2C-E,
lipid raft disruption downregulated uPAR, MMP-9 and
uPA activity and protein expression in both MDA-MB-
231 and ZR 751 cells. As a consequence, we assessed
whether lipid raft disruption affects gene expression in
breast carcinoma cells. MDA-MB-231 and ZR 751 cells
were left untreated or pretreated with different concen-
trations of MbCD for one hour at 37°C, and total RNA
was extracted at 4, 8 and 24 hrs. uPAR mRNA and
MMP-9 mRNA levels were measured by semi-
quantitative RT-PCR. As shown in Figures 4C-D, we
observed significant inhibition of uPAR mRNA in both
MDA-MB-231 and ZR 751 cells at early time points up
to 8 hrs after treatment. mRNA analysis at the 24 hr
time point showed no changes in uPAR mRNA or
MMP-9 mRNA in LR-disrupted cells (data not shown).
These results further strengthened our previous findings,
and the downregulation of uPAR and MMP-9 protein
levels upon lipid raft disruption could be due to down-
regulation of uPAR and MMP-9 gene expression at ear-
lier time points. Taken together, these results suggest
that lipid rafts play an active role in the modulation of
uPAR and MMP-9 activities in both MDA-MB-231 and
ZR 751 cells. The observed decrease in uPAR and
MMP-9 activity upon lipid raft disruption in both cell
lines could be very critical to the cellular proliferation of
breast carcinoma.
Figure 3 Effect of MbCD and nystatin on MDA-MB-231 and ZR 751 cells. (A) and (B). Cholesterol depletion/chelation by MbCD and
nystatin. MDA-MB-231 and ZR 751 cells were treated with different concentrations of MbCD and nystatin for 1 hr, and cholesterol levels were
measured at 1 and 24 hrs in (A) MDA-MB-231 and (B) ZR 751 cells. The percentage reduction in cholesterol upon drug treatment was calculated
with respect to total cholesterol in the untreated cells, which is taken as 100%. Each reaction was performed in duplicate and each point
represents the mean ± S.D. of three independent experiments. (C) MDAMB 231 and ZR 751 cells were incubated with different concentrations of
MbCD for 1 h, 4 h, 24 h and 48 h. Supernatants were collected and assessed for cellular toxicity by using a lactate dehydrogenase assay kit. The
data is represented as percentage cytoxicity with reference to untreated cells.
Raghu et al. BMC Cancer 2010, 10:647
http://www.biomedcentral.com/1471-2407/10/647
Page 8 of 17Figure 4 Lipid raft disruption reduces uPAR and MMP-9 activity in lipid raft fractions of MDA-MB-231 and ZR 751 cells.( A )&( B )
Characterization of lipid raft fractions. (A) MDA-MB-231 and (B) ZR 751 cells were left untreated or pretreated with 10 mM MbCD for one hour. Cells
were washed, lysed, and raft and non-raft fractions were collected as described earlier. Fractions were characterized as raft fractions or non-raft
fractions and western blotted for caveolin or flotillin (raft marker) and transferrin (non-raft marker). Fractions 3 to 5 were pooled as raft fractions,
and pooled fractions 6 to 8 were taken as non-raft fractions. (C) & (D) Effect of lipid raft disruption on uPAR and MMP-9 gene expression in breast
carcinoma cells. (C) MDA-MB-231 and (D) ZR 751 cells were left untreated or pretreated with different concentrations of MbCD for one hour,
washed, complete medium added, and total RNA isolated at 8 h using the TRIzol method. 50 ng of DNAse-treated RNA/μL were subjected to semi
quantitative RT-PCR with primers specific for uPAR and MMP-9. Expression of GAPDH was used to verify equal loading of cDNA. (D) Densitometric
analysis of uPAR and MMP-9 expression at the mRNA level (mean ± SE, n = 3) (*p < 0.001, **p < 0.0001).
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Page 9 of 17Lipid raft disruption downregulates the levels of
phosphorylated Src, FAK, caveolin, PI3-K, Akt and ERK in
MDA-MB-231 and ZR 751 cells
Previous studies have shown that Src is associated with
lipid raft domains in different cell types [3]. To determine
if lipid raft disruption affected Src phosphorylation,
lysates prepared from MDA-MB-231 cells before and
after treatment with 7.5 and 10 mM MbCD were
probed with antibodies against phospho-Src pY416. As
expected, Src phosphorylation was high in untreated
cells (Figure 5A, upper panel, lane 1). In cells pretreated
with MbCD, there was significant downregulation of
phospho-Src in both MDA-MB-231 and ZR 751 cells.
Previous studies from our lab have shown that uPAR
activation in breast carcinoma cells activates Src, FAK,
PI3-K and Akt signaling pathways [24]. As most of
these signaling molecules are associated with lipid rafts
[3], we wanted to check if lipid raft disruption regulates
these signaling molecules in both MDA-MB-231 and
ZR 751 cells. Western blotting analysis of the lysates
revealed higher levels of pFAK, pPI3-K, pAkt, pCav and
pERK in untreated MDA-MB-231 and ZR 751 cells
(Figures 5A-B). We observed significant reductions in
the phosphorylated levels of FAK, Akt, PI3-K, caveolin
and ERK in LR-disrupted cells when compared with
untreated cells (Figures 5A-B, lanes 2 and 3). Equal
loading of total lysates was confirmed by GAPDH. We
did not find significant differences in the total levels of
Src, FAK, caveolin, ERK and Akt. These results suggest
that lipid rafts play a significant role in Src, FAK, PI3-K,
Akt and caveolin phosphorylation in MDA-MB-231 and
ZR 751 cells.
To further confirm our results, immunofluorescent
analysis of untreated and LR-disrupted cells revealed
association of FAK, pCav, and PI3-K with the LR mar-
ker GM1 in untreated MDA-MB-231 cells (Figure 5C,
panels c, i and o) and the absence of this colocalization
in MbCD-treated cells (Figure 5C, panels f, l and r).
Similar results were observed with pSrc and pERK (data
not shown). Overall, these results suggest that lipid rafts
play a critical role in Src, FAK, caveolin, ERK and Akt
phosphorylation in MDA-MB-231 and ZR 751 cells.
Lipid raft disruption by cholesterol depletion inhibits
migration and invasion of MDA-MB-231 and ZR 751 cells
Previously in Figures 1 &2 we have shown that LR dis-
r u p t i o ni nM D A - M B - 2 3 1a n dZ R7 5 1c e l l si n h i b i t e d
uPAR and MMP-9 activity. Consequently, we evaluated
whether LR disruption affects migration and invasion of
breast carcinoma cells. Figure 6A shows spheroids,
which were left untreated, had a high number of cells
that migrated from the spheroids into the surrounding
area. However, LR-disrupted cells failed to migrate,
which resulted in no migration (Figure 6A, panels a to
f). MDA-MB-231 cells were left untreated or pretreated
with different concentrations of MbCD and allowed to
invade through Matrigel-coated filters. Figure 6B shows
the staining of LR-disrupted MDA-MB-231 cells was
significantly less than that of the untreated cells. Quanti-
tative analysis of spheroid migration in MDA MB231
and ZR 751 cells before and after treatment with MbCD
showed 50-70% reduction in migration (Figure 6C).
Quantitative analysis of the cells showed that only 30-
40% of the LR-disrupted MDA MB231 cells invaded the
Matrigel as compared to the untreated cells (Figure 6D).
Taken together, these findings provide strong evidence
that by modulating the lipid rafts in breast carcinoma
cells, the migration and invasion of MDA-MB-231 cells
and ZR 751 cells are significantly inhibited as compared
to cells in which the integrity of the lipid rafts were
maintained. These results indicate that lipid rafts are
critical for the migratory and invasive properties of
breast carcinoma cells.
Lipid raft disruption by cholesterol depletion inhibits
angiogenesis of MDA-MB231 and ZR 751 cells
As studies have shown that cholesterol depletion plays a
critical role in VEGF signaling [26], we determined
whether cholesterol depletion by MbCD plays a role in
the angiogeneic potential of breast carcinoma cells. Con-
ditioned medium prepared from the supernatants of
MDA-MB-231 and ZR 751 cells that were left untreated
or pretreated with different concentrations of MbCD
were cultured with human microvascular endothelial
cells. We evaluated the tumor conditioned medium-
induced vessel formation using an in vitro angiogenesis
assay. The results showed that conditioned medium pre-
pared from cells that were treated with MbCD signifi-
cantly reduced the capacity of endothelial cells to form
capillary-like structures (Figure 6E, panels b, c, e and f).
In contrast, conditioned medium from untreated cells
resulted in well-formed capillary-like structures by the
48 hr time point (Figure 6E, panels a and d). The quan-
tification of branch points and number of branches con-
firmed a significant reduction in the MbCD-treated
samples when compared with the untreated cells (Figure
6F). These results suggest that lipid raft disruption
downregulates the angiogenic potential of breast carci-
noma cells.
Lipid raft disruption by cholesterol depletion enhances
the secretion of soluble uPAR in the conditioned medium
of breast carcinoma cells
After having demonstrated the effect of lipid raft disrup-
tion on uPAR protein expression in the cell lysates of
breast carcinoma cells, we assessed the levels of soluble
uPAR in the conditioned medium of LR-disrupted cells
at 48 hrs. We used a commercially available uPAR
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Page 10 of 17Figure 5 Lipid raft disruption inhibits the levels of pSrc, pFAK, pCav, pERK, pAkt, pPI3-K, and pAkt in breast carcinoma cell lines.( A )
and (B) MDA-MB-231 and ZR 751 cells left untreated or pretreated with different concentrations of MbCD were subjected to Western blot
analysis for total and phosphorylated forms of Src, FAK, Cav, ERK, PI3-K, and Akt. GAPDH was used to verify that similar amounts of protein were
loaded in each lane. Densitometric analysis of phosphorylated molecules was done. The result provided is of a representative experiment
repeated 3-4 times with concordant results (*p < 0.01, **p < 0.001). (C) MDA-MB-231 cells were left untreated or pretreated with 7.5 mM MbCD
for 1 hr at 37°C, washed, labeled with primary antibodies to GM1 by Vybrant lipid raft labeling kit, fixed, permeabilized, incubated with pFAK,
pCav and pPI3-K antibodies and appropriate secondary antibodies. The cells were washed, stained with DAPI containing anti-fade agent, and
visualized by confocal immunofluorescence microscopy.
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Page 11 of 17Figure 6 Lipid raft disruption inhibits migration, invasion and angiogenesis of breast carcinoma cell lines. (A) Lipid raft disruption inhibits the
migration of breast carcinoma cells. Intact MDA-MB-231 and ZR 751 cell spheroids of approximately the same diameter were selected. Spheroids were
then transferred in serum-free medium, left untreated or treated with different concentrations of MbCD, and incubated for 48 hrs to allow for
migration. Finally, cell migration was observed using a laser scanning microscope. (B) Lipid raft disruption inhibits the invasion of breast carcinoma
cells. MDA-MB-231 cells (1 × 10
6) were left untreated or pretreated with different concentrations of MbCD, washed, and allowed to migrate through
Matrigel-coated transwell inserts (8-μM pores) for 24 hrs. The cells that invaded through the Matrigel-coated inserts were stained, counted and
photographed under a light microscope. (C) Quantification of relative migration. (D) The percentage of invasion was quantified as described earlier.
Values represented are mean ± S.D from three different experiments (**p < 0.001). (E) Lipid raft disruption inhibits angiogenesis of breast carcinoma
cells. Conditioned media from MDA-MB-231 and ZR 751 cells, which were left untreated or pretreated with MbCD, were collected at 24 hr. 8 × 10
3
human microvascular endothelial cells (HMEC) were cultured in the collected conditioned medium in 48-well plates for 24 hrs. After the incubation
period, the medium was removed, and the cells stained with Hema-3 stain and examined under a microscope. (F) Quantification of angiogenesis in
endothelial cells that were left untreated or pretreated with MbCD. Values are mean ± S.D. from three different experiments (*p < 0.01, **p < 0.001).
(G) Lipid raft disruption increases the secretion of soluble uPAR. MDA-MB-231 and ZR 751 cells were left untreated or pretreated with MbCD, and
conditioned medium was collected at the 48 hr. suPAR levels were measured and quantified by ELISA as per the manufacturer’s instructions.
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Page 12 of 17immunoassay detection kit (R&D Systems) and per-
formed the assay as per the manufacturer’s instructions.
As shown in Figure 6G, we observed a 7-to 8-fold
increase in soluble uPAR levels in MDA-MB-231 cells
pretreated with the LR-disrupting agent MbCD and a
5-to 6-fold increase in soluble uPAR levels in ZR 751
cells pretreated with MbCD. Overall, these results sug-
gest that lipid raft disruption promotes the removal of
uPAR from the plasma membrane, and the released
soluble uPAR is secreted for at least 48 hrs in breast
carcinoma cells.
Lipid raft disruption by cholesterol depletion results in
uPAR trafficking to the lysosomal pathway in MDA-MB-
231 cells
uPAR is known to cycle back to the plasma membrane
after it has been endocytosed with LRP, PAI and uPA
[27]. To study the fate of uPAR after lipid raft disrup-
tion, we carried out trafficking studies of uPAR at differ-
ent time points using immunofluorescent staining for
LAMP-1, a lysosomal marker, and uPAR at 1, 8 and 24
hr time points. In untreated cells, we observed very little
colocalization of uPAR with LAMP-1 in MDA-MB-231
cells, suggesting that the majority of uPAR is not tar-
geted to the lysosomal pathway in LR-intact cells (Figure
7A, panels a to i). However, in LR-disrupted cells, we
observed significant colocalization of uPAR with LAMP
1 as early as one hour after treatment (Figure 7B, panels
a to c) and further increased by 8 hrs (Figure 7B, panels
d to f) and 24 hrs (Figure 7B, panels g to i). The results
suggest that lipid raft disruption causes the targeting of
uPAR to the lysosome, which may contribute signifi-
cantly to the loss of the uPAR function in breast cancer
cells.
Cholesterol supplementation reverses the downregulated
uPAR levels to basal levels in MDA-MB-231 and ZR 751
cells
To further examine a possible role for cholesterol in the
downregulation of uPAR in MDA-MB-231 and ZR 751
cells, MDA-MB-231 and ZR 751 cells were left
untreated, treated with MbCD alone or cholesterol addi-
tion after cholesterol depletion. Lysates were prepared
and subjected to immunoblotting analysis. MbCD-
induced downregulation of uPAR levels in MDA-MB-
231 and ZR 751 cells were reversed by the addition of
cholesterol as assessed by immunoblotting (Figures 8A-
B). These results indicate that cholesterol repletion
reverses the MbCD-induced uPAR activity in breast car-
cinoma cells.
Discussion
The present study shows that lipid raft disruption by
cholesterol depletion could significantly attenuate inva-
sion, migration and angiogenesis in breast carcinoma
cells. These functions are mediated by the
Figure 7 Time course studies of uPAR before and after lipid raft disruption in MDA-MB-231 cells. MDA-MB-231 cells were left untreated
or pretreated with 7.5 mM MbCD for one hour at 37°C; washed; fixed with 1% paraformaldehyde at 1, 8 and 24 hrs; permeabilized; incubated
with primary antibodies against uPAR and LAMP-1 overnight at 4°C; washed; incubated with appropriate Alexa Fluor secondary antibodies; and
mounted with an anti-fading agent containing DAPI. The cells were imaged under an Olympus fluoview confocal microscope.
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Page 13 of 17downregulation of uPAR and MMP-9 and their asso-
ciated signaling molecules. We have looked at the role
of lipid rafts in breast cancer cells by means of choles-
terol depletion using MbCD, which has been used in
many studies [3,28-30]. Previous studies from our lab
[31] have shown that bicistronic constructs against
uPAR and MMP-9 have significant inhibitory potential
against many types of cancer, particularly breast cancer.
As both uPAR and MMP-9 are associated with lipid raft
microdomains, we wanted to study the effect of lipid
raft disruption in the modulation of uPAR and MMP-9
and their associated signaling molecules. Moreover, as
cholesterol is a major component of lipid rafts, depletion
of cholesterol has been employed to elucidate the role of
LR domains.
L i p i dr a f t sa r eas o u r c eo fm a n ys i g n a l i n gp r o t e i n s
including Src, FAK, heterotrimeric G protein subunits
and receptor tyrosine kinases [4]. Lipid rafts have been
implicated in many types of cancer, and cholesterol
accumulation in different types of cancer is well estab-
lished [32,33]. However, few studies have addressed the
effect of lipid raft disruption on the invasive, migratory
and angiogenic potential of cancer cells. Studies have
shown that uPAR, a GPI anchored protein, is a lipid raft
resident protein [34]. Cunningham et al. [7] have shown
that the dimeric form of uPAR was particularly enriched
in the lipid rafts. They also showed that uPA-induced
uPAR cleavage was strongly accelerated in the lipid
rafts. In the present study, we observed significant asso-
ciation of uPAR with lipid rafts in both MDA-MB-231
and ZR 751 cells using morphological methods and bio-
chemical isolation of LR fractions in breast carcinoma
cells. Whether the lipid rafts of MDA-MB-231 or ZR
751 cells contain the monomeric form or the dimeric
form of uPAR was not evaluated in this study.
In the present study, we demonstrate that cholesterol
depletion by MbCD lowers the surface expression of
uPAR and MMP-9 in breast carcinoma cells. Cholesterol
lowering agents like MbCD cause disintegration of lipid
rafts and block signaling, thereby suggesting that choles-
terol is very critical for LR formation and also its func-
tion. Many studies have shown that LR domains are
rich in survival-related molecules like PI3-K/Akt and
ERK [3]. Our results are in agreement with Li et al. [28]
Figure 8 Supplementation of cholesterol reverses the effect of lipid raft disruption on uPAR levels in MDA-MB-231 and ZR 751 cells.
Serum-starved (A) MDA-MB-231 and (B) ZR 751 cells were left untreated, treated with different concentrations of MbCD, or treated with 10 mM
MbCD and supplemented with 2 mM cholesterol. The cells were lysed, and 80 μg of protein from each treatment were subjected to
immunoblotting analysis using anti-uPAR and GAPDH antibodies. Similar results were observed in two separate experiments. Abbreviations:
uPAR-urokinase plasminogen activator receptor; MMP-matrix metalloproteinase 9, LR - lipid raft, MbCD - Methyl beta cyclo dextrin.
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Page 14 of 17who demonstrated downregulation of Akt in MCF-7 and
MDA-MB-231 cells due to elevated levels of rafts in
these cells. Studies have also shown that lipid rafts are
critical for the function of the Src family of kinases
[35,36]. In the present study, we were able to see that
LR disruption in MDA-MB-231 cells significantly
reduced levels of PI3-K and Src.
Cholesterol depletion resulted in lipid raft internaliza-
tion associated with FAK downregulation, which prob-
ably affected cell adhesion. Cell adhesion is mediated by
integrins and lipid raft disruption could affect their
interaction, which could have resulted in the loss of cell
adhesion. Currently, studies of the association of integ-
rins with LR domains in breast carcinoma cells are
under investigation. In our study, we observed that LR
disruption by cholesterol depletion reduced levels of
uPAR and MMP-9 in breast carcinoma cells as shown
by Western blotting and fibrin and gelatin zymography.
Previous studies from our lab have shown that uPAR is
associated with integrins such as a5b3 and receptors
[37]. Moreover, others have shown that the addition of
cholesterol increases cell adhesion via ganglioside GM3,
which is present in lipid raft domains and a5b1 [38].
Based on our results, it is possible that MbCD treatment
alters uPAR and MMP-9 functions and integrin func-
tion, which results in decreased cell proliferation and
invasion. We are also in the process of determining the
role of other signaling molecules like Rho GTPases and
lipid rafts in breast carcinoma cells.
Interestingly, we also observed FAK downregulation
upon cholesterol depletion in breast carcinoma cells.
This is in accordance to a recent study done by Park
et al. [39], which demonstrated that cholesterol is criti-
cal for FAK-mediated cell survival. The study showed
that FAK activation might prevent caveolae internaliza-
tion, which allows for cell survival signaling like the PI3-
K signaling pathway. In our present study, exogenous
cholesterol supplementation reversed the levels of uPAR
to their basal levels. However, how this phenomenon
was induced is still not clear. Our results also showed
that lipid raft disruption targets uPAR to the lysosome
in MDA-MB-231 cells. As previous studies have shown
that cholesterol accumulation is associated with cancer
progression [32,33], the targeting of lipid rafts for cancer
therapy has been suggested [40,41]. Studies by Zhuang
et al. [42] have shown that certain tumors, which are
dependent on PI3-K/Akt pathway, are susceptible to
cholesterol-targeted drug therapy. Although their con-
tention is largely true, cholesterol depletion also alters
uPAR and MMP-9 activity. As shown by immunoassay,
the levels of soluble uPAR upon lipid raft disruption in
the conditioned medium were increased in cells pre-
treated with a lipid raft disrupting agent at the 24 hr
time point in both cell lines. As determined by
zymography, uPA levels in conditioned medium were
significantly down regulated upon lipid raft disruption at
the 24 hr time point in both cell lines. These results
suggest that an intact lipid raft is critical for efficient
cancer cell proliferation, and altering its integrity could
significantly affect its invasive and migratory properties.
It is well known that several proteases are present in
lipid rafts, and they are thought to play a critical role in
tumor cell invasion, metastasis and angiogenesis [43-48].
Endothelial cell migration and invasion was also
enhanced by rafts enriched with MMP-2/MMP-9
[45,47,48]. In particular, MMP-9 has been shown to play
a critical role in tumor invasion, wound healing, metas-
tasis and angiogenesis [10]. Here, we have demonstrated
that cholesterol depletion by MbCD reduced MMP-9
protein levels in the lysates of MDA-MB-231 and ZR
751 cells. We were also able to show that uPAR down
regulation by cholesterol depletion was inhibited by cho-
lesterol supplementation.
Consistent with our results, cholesterol depletion has
been shown to downregulate phospho-Akt and phos-
pho-ERK, which play critical roles in cell survival and
induce apoptosis [28]. In the present study, we observed
MMP-9 down regulation at the mRNA level at early
time points (up to 8 hrs) in MDA-MB-231 and ZR 751
cells. The MMP-9 promoter is known to have several
transcription factor-binding motifs, which include AP-1,
NF-B and Sp-1 [49]. Whether LR disruption in MMP-
9 inhibition activates AP-1, NF-B or SP1 will have to
be evaluated at a future date. Zhang et al. [14] have
shown that when highly metastatic mouse Lewis lung
carcinoma cells were treated with MbCD, their invasive
capacity was suppressed and MMP-9 activity in the lipid
rafts was inhibited. We observed similar results regard-
ing MMP-9 in MDA-MB-231 and ZR 751 cells, which
was contradictory to the study by Kim et al. [50] who
have shown that in human keratinocytes, cholesterol
depletion increased MMP-9 activity. As assessed by in
vitro angiogenesis assay, cholesterol depletion in breast
carcinoma cells affects their angiogenic potential. Stu-
dies to understand the molecular mechanisms of the
inhibition of angiogenesis and the role of lipid rafts in
this process are under progress.
Conclusions
To summarize, intracellular cholesterol depletion by LR
disruption downregulates MMP-9 and uPAR levels and
uPAR trafficking in breast carcinoma cells. Our results
also show that cholesterol depletion in breast cancer
cells downregulates ERK-and JNK-dependent pathways,
thereby leading to downregulation of uPAR and MMP-9
expression. Cholesterol supplementation did reverse the
change in uPAR expression levels. Therefore, decreasing
cholesterol levels by LR disruption could provide a good
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Page 15 of 17strategy to prevent MMP-9 and uPAR-mediated degra-
dation of the extracellular matrix in breast carcinoma.
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